NSE: ROSSARI | BSE: 543213

Mid-range Performer

Download real time

618.15 0.90 (0.15%)

36.45% Fall from 52W High

31,333 NSE+BSE Volume

NSE 29 Aug, 2025 3:31 PM (IST)

3,422.5

Market Cap

Above industry Median

0.7

Beta 1Year

Very Low volatility

Rossari Biotech Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ROSSARI, BSE:543213 Rossari Biotech Ltd.

Rossari Biotech Ltd.

03 May 2023

618.15

0.15%

Unexciting performance

Hold: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech’s Q4FY23 revenue dipped 7.4% YoY (rose 4.4% QoQ) to Rs4.1bn due to drop in raw material prices. However, we were disappointed by a 40bps QoQ contraction in gross profit margin to 29.6%. EBITDA growth therefore was just 4.3% YoY.

Rossari Biotech Ltd. is trading below all available SMAs

Rossari Biotech Ltd.

03 May 2023

618.15

0.15%

Rossari Biotech | Q4FY23 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

Signs of a recovery in sight

Rossari Biotech Ltd. has lost -31.15% in the last 1 Year

Rossari Biotech Ltd.

07 Feb 2023

618.15

0.15%

Is worst behind for revenue growth and margins?

Accumulate: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech’s Q3FY23 performance disappointed with 9.1% YoY / 8.5% QoQ dip in revenues to Rs3.9bn. However, EBITDA margins showed recovery, up 60bps QoQ to 13.9%. Revenues were hurt due to multiple reasons: 1) lower realisation as a result of softening raw material prices; 2) complete exit of a large customer; 3) underlying headwinds for textile industry; and 4) muted performance by acquired companies.

Rossari Biotech Ltd. has lost -31.15% in the last 1 Year

Rossari Biotech Ltd.

11 Nov 2022

618.15

0.15%

Rossari Biotech Ltd | Q2FY23 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

Synergies and product introductions to drive long-term growth

Rossari Biotech Ltd. is trading below all available SMAs

Rossari Biotech Ltd.

09 Nov 2022

618.15

0.15%

After margins, revenue has headwinds now!

Hold: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech’s Q2FY23 result disappointed on margins despite raw material price
correction, and now company is cautious on revenue growth. We are disappointed at
revenue growth performance across segments of standalone business.

Rossari Biotech Ltd. has lost -31.15% in the last 1 Year

Rossari Biotech Ltd.

11 Aug 2022

618.15

0.15%

Rossari Biotech Ltd. | Q1FY23 Result Update

Buy: Rossari Biotech Ltd.

Edelweiss

Margins inching up, 2H expected to be stronger

Rossari Biotech Ltd. has an average target of 926.25 from 4 brokers.

Rossari Biotech Ltd.

10 Aug 2022

618.15

0.15%

Protecting margins; revenue growth tepid

Hold: Rossari Biotech Ltd.

Target

ICICI Securities Limited

Rossari Biotech’s Q1FY23 result was a mixed print with weak revenue (standalone revenue dipped 11% QoQ / up 15% YoY), while margin displayed sharp recovery (gross profit margin up 300bps QoQ).

Number of FII/FPI investors decreased from 82 to 65 in Jun 2025 qtr

Rossari Biotech Ltd.

26 May 2022

618.15

0.15%

Rossari

Buy: Rossari Biotech Ltd.

Yes Securities

Number of FII/FPI investors decreased from 82 to 65 in Jun 2025 qtr

Rossari Biotech Ltd.

25 May 2022

618.15

0.15%

Rossari Biotech Ltd | Q4FY22 Result Update

Buy: Rossari Biotech Ltd.

Target

Edelweiss

Acquired businesses outperform, Outlook Positive

Rossari Biotech Ltd. has an average target of 926.25 from 4 brokers.

Rossari Biotech Ltd.

24 May 2022

618.15

0.15%

Company putting in efforts to normalize margins

Hold: Rossari Biotech Ltd.

ICICI Securities Limited

Rossari Biotech’s Q4FY22 standalone EBITDA dipped 20% YoY to Rs275mn, and standalone HPPC revenues fell 13% QoQ – which were unimpressive. However, the performance of acquired companies was steady, and this helped consolidated EBITDA growth of 49% YoY to Rs523mn.

Rossari Biotech Ltd. is trading below all available SMAs

VOTE: Is Rossari Biotech Ltd. worth buying?

68 Votes:

Buy 89.71%

Sell 4.41%

Hold 5.88%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf link